Terns has a modest market cap of less than $800 million, and its possible upside could be massive.
Terns Pharmaceuticals just proved that it's competitive in the weight loss field.
Getting in on the ground floor sounds like a great idea, but not if the building ends up crumbling.
This biotech's data suggests that it could have an advantage in its target market.
At least one of the pair has a credible shot at finding a home in the market.
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to combat obesity. Is TERN stock a good buy right now?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
NASH treatments are projected to be one of the most sought-after indications in the coming years.
NASH is a surprisingly common ailment, and the first treatments are on the way.
The company is showing progress toward a NASH therapy.